Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
idiopathic pulmonary fibrosis
Biotech
PureTech creates Celea to develop promising lung disease drug
Using its hub-and-spoke model, PureTech is launching a new subsidiary, Celea Therapeutics, to develop its candidate for the rare lung disease IPF.
Kevin Dunleavy
Aug 12, 2025 10:46am
Contineum shifts cash from MS to lung disease showdown with BMS
Aug 6, 2025 9:51am
Boehringer 'crossing fingers' ahead of 2 key FDA approvals
Jul 24, 2025 3:00am
Pliant ends lung disease program over rise in adverse events
Jun 30, 2025 4:49am
Transpire licenses PDE4 inhibitor for lung disease
Jun 3, 2025 9:45am
PureTech's deupirfenidone shows durable effect in IPF study
May 20, 2025 5:15pm
